SHANGHAI – Taiwan Liposome Co. (TLC) is hoping to give patients with osteoarthritis of the knee a better option for pain management with TLC599, a steroid API wrapped in a sustained release liposome delivery package. The company released positive top line results from a phase I/II data for a trial in Taiwan and Australia, and kicked off a phase II trial in both places with plans underway for China and the U.S.